{"database": "lobbying", "table": "lobbying_activities", "rows": [[3478829, "c0c76b42-bb38-478d-a6e4-79ee7b0b19b6", "Q4", "MAGILL ASSOCIATES, LLC", 401103511, "THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES", 2025, "fourth_quarter", "MED", "FY 2026 appropriations for the development of a synthetic vaccine", "HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2026-01-06T15:46:47-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3478829"], "units": {}, "query_ms": 5.678936024196446, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}